Literature DB >> 28821386

Serum and follicular fluid testosterone concentrations do not correlate, questioning the impact of androgen supplementation on the follicular endocrine milieu.

Michael von Wolff1, Petra Stute2, Markus Eisenhut2, Ulrich Marti3, Norman Bitterlich4, Nick A Bersinger2.   

Abstract

Basic research into a possible link between serum and follicular fluid androgen concentrations to detemine whether androgen supplementation in low responders affects follicular endocrine milieu is still lacking. Ninety-seven women (aged 28-43 years) undergoing one natural IVF cycle without any hormone stimulation were analysed. Serum and follicular fluid were collected at the time of follicle aspiration, and the concentrations of LH, total testosterone, oestradiol, dehydroepiandrosterone and anti-Mullerian hormone (AMH) were determined. Serum LH (P = 0.003) and AMH (P = 0.026) concentrations, and follicular fluid AMH (P = 0.015) decreased with increasing age. Within follicular fluid, total testosterone was correlated with oestradiol (P < 0.001) and AMH (P = 0.010); LH correlated with AMH (P = 0.005). Correlation analysis of serum and follicular fluid hormone concentrations revealed that LH, oestradiol and AMH correlated (P < 0.001), whereas testosterone did not. Testosterone serum concentrations did not correlate with other follicular fluid hormones, such as dehydroepiandrosterone, oestradiol and AMH, whereas serum LH correlated with follicular flulid AMH (P < 0.008). Follicular fluid hormone concentrations seem to be independent from serum testosterone. Therefore, it is questionable whether an increase in serum testosterone concentration by androgen supplementation could improve the follicular endocrine milieu.
Copyright © 2017. Published by Elsevier Ltd.

Entities:  

Keywords:  Anti-Müllerian hormone; Follicular fluid; LH; Natural cycle IVF; Testosterone

Mesh:

Substances:

Year:  2017        PMID: 28821386     DOI: 10.1016/j.rbmo.2017.07.012

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  5 in total

Review 1.  The Role of Androgen Receptor Signaling in Ovarian Cancer.

Authors:  Taichi Mizushima; Hiroshi Miyamoto
Journal:  Cells       Date:  2019-02-19       Impact factor: 6.600

2.  Commentary: Management Strategies for POSEIDON Groups 3 and 4.

Authors:  Klaus F Bühler
Journal:  Front Endocrinol (Lausanne)       Date:  2020-01-24       Impact factor: 5.555

3.  Recombinant human luteinizing hormone co-treatment in ovarian stimulation for assisted reproductive technology in women of advanced reproductive age: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Alessandro Conforti; Sandro C Esteves; Peter Humaidan; Salvatore Longobardi; Thomas D'Hooghe; Raoul Orvieto; Alberto Vaiarelli; Danilo Cimadomo; Laura Rienzi; Filippo Maria Ubaldi; Fulvio Zullo; Carlo Alviggi
Journal:  Reprod Biol Endocrinol       Date:  2021-06-21       Impact factor: 5.211

Review 4.  Biological and Clinical Rationale for Androgen Priming in Ovarian Stimulation.

Authors:  Kristine Løssl; Nina la Cour Freiesleben; Marie Louise Wissing; Kathrine Birch Petersen; Marianne Dreyer Holt; Linn Salto Mamsen; Richard A Anderson; Claus Yding Andersen
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-04       Impact factor: 5.555

5.  Effect of rLH Supplementation during Controlled Ovarian Stimulation for IVF: Evidence from a Retrospective Analysis of 1470 Poor/Suboptimal/Normal Responders Receiving Either rFSH plus rLH or rFSH Alone.

Authors:  Stefano Canosa; Andrea Roberto Carosso; Noemi Mercaldo; Alessandro Ruffa; Francesca Evangelista; Francesca Bongioanni; Chiara Benedetto; Alberto Revelli; Gianluca Gennarelli
Journal:  J Clin Med       Date:  2022-03-13       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.